Navigation Links
De nouvelles données mettent en évidence le fardeau considérable que représente la nycturie
Date:3/17/2013

MILAN, March 17, 2013 /PRNewswire/ --

Affection chronique associée à des troubles du sommeil et à une perte notable

de productivité et d'activité non liée au travail

De nouvelles données présentées aujourd'hui au congrès de l'Association européenne d'urologie (EAU) montrent que la nycturie (le besoin d'uriner une ou plusieurs fois la nuit) est associée à une réduction importante de la productivité au travail et des activités de loisirs, de manière semblable à d'autres troubles chroniques comme l'asthme, la BPCO (bronchopathie obstructive chronique) et le RGO (reflux gastro-oesophagien).[1] Il a été démontré que la nycturie réduisait de près de 25 % la productivité au travail de la population active.[1]

Par ailleurs, d'autres résultats d'étude montrent que chez ceux qui en souffrent, les troubles du sommeil représentent le symptôme le plus difficile à supporter. Environ un tiers des personnes souffrant de nycturie sont incapables de retrouver le sommeil et deviennent insomniaques.[2]

La fragmentation du sommeil est une conséquence grave de la nycturie et peut affecter négativement les performances dans la journée.  Une analyse des données obtenues à partir de deux études cliniques randomisées et contrôlées (n=646) sur trois mois, a été effectuée dans le cadre d'une évaluation économique visant à comparer les effets de la nycturie sur la productivité et l'activité par rapport à d'autres maladies chroniques.  La productivité au travail a été évaluée grâce au questionnaire sur la dégradation de l'activité et de la productivité au travail.[3]

'/>"/>
SOURCE Ferring Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Elsevier Launches Evidence-Based, Collaborative Order Sets Solution
2. More evidence needed for scale up of mobile device technology in health
3. Caris Life Sciences Adds Next-Generation Sequencing to Enhance Evidence-Based Tumor Profiling Service for Cancer Patients
4. First Evidence that Adipose Stem Cell-Based Critical Limb Ischemia Treatment is Safe & Effective is published in Circulation Journal by Lead Investigator Dr. Han Cheol Lee of Pusan National University
5. endpoint Adopts New Technology To Boast Most Robust IVR Validation Objective Evidence and Decrease IVR Build Timelines
6. New Epidemiological Data Provide Additional Safety Evidence for Lantus®
7. More evidence for longevity pathway
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... IRVING, Texas , May 29, 2015 /PRNewswire/ ... company focused on fulfilling the promise of precision ... five studies that demonstrate the clinical utility of ... comprehensive tumor profiling service, in helping to identify ... aggressive tumors. In each of the studies, results ...
(Date:5/29/2015)... (PRWEB) May 29, 2015 Seoul ... leader in LED technology, on May 28th announced ... market share by strengthening its high efficient and ... application , Since 2011 Seoul Semiconductor has developed ... lighting market and has supplied LEDs for headlamps ...
(Date:5/28/2015)... May 28, 2015  Quest Diagnostics Incorporated (NYSE: ... services, announced that it is scheduled to speak at ... Steve Rusckowski , the company,s President and CEO, ... strategy.  The presentation is scheduled for Tuesday, June 2, ... presentation will be webcast live during the conference and ...
(Date:5/28/2015)... 27, 2015 Research and Markets( http://www.researchandmarkets.com/research/6cg3zw/cell_therapy ... new report "Cell Therapy - Technologies, Markets ... This report describes and evaluates cell therapy technologies ... an important role in the practice of medicine. ... fashioned bone marrow transplants. Role of cells in ...
Breaking Biology Technology:Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 2Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 3Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 4Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 5Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 6Seoul Semiconductor Increases the Global Automotive LED Market Share with its High Efficient and Reliable LEDs for Automotive Lightings 2Quest Diagnostics to Speak at the Jefferies 2015 Global Healthcare Conference 2Global Cell Therapy Market 2015-2020 - Technologies, Markets and Companies 2
... N.Y. , July 29 On ... Publication Professionals (ISMPP) and the Medical Publishing Insights and ... various MPIP initiatives ( http://www.mpip-initiative.org ). The web page ... MPIP initiative, updating viewers on new or planned activities, ...
... , Saliva-Based DNA Collection Product Chosen for Study to Identify ... , , ... /PRNewswire/ - DNA Genotek, a leading provider of products ... the world,s leading TB vaccine research site, the South African ...
... , VANCOUVER , July 28 ... ANP) ("Angiotech") and partner Athersys, Inc. (NASDAQ: ATHX) ... trial of MultiStem(R), its allogeneic cell therapy product, ... more commonly referred to as a heart attack. ...
Cached Biology Technology:ISMPP and MPIP Announce New Medical Publishing Website 2ISMPP and MPIP Announce New Medical Publishing Website 3DNA Genotek's Oragene-DNA Achieves 95% Compliance Rate in South African Tuberculosis Vaccine Initiative (SATVI) 2DNA Genotek's Oragene-DNA Achieves 95% Compliance Rate in South African Tuberculosis Vaccine Initiative (SATVI) 3Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 2Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 3Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 4Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 5Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 6Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 7Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 8Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 9
(Date:5/21/2015)... , May 21, 2015 The ... potential of music for health, today announced a collaborative ... . The partnership will center on collaboration on original ... a first step in the collaboration, The Sync Project ... on "Music as Medicine" in the 2015-2016 academic year.  ...
(Date:5/20/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... subsidiary, 3D-ID LLC, a company engaged in biometric identification ... biometrics technology portion of the recently awarded TIES (Technical ... of the Army. 3D-ID LLC has a ... law enforcement and security agencies. Gino ...
(Date:5/19/2015)... NEW YORK , May 19, 2015  Technology ... resources both internally and in the cloud. Passwords and ... the use of OTP and standards-based specifications such as ... that the outmoded use of passwords presents for BYOD, ... needs a unified biometric identity protocol. ...
Breaking Biology News(10 mins):The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 2HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 3
... Goldfarb LLP is investigating whether the board of ... shareholder protection laws as evidenced through alleged inconsistencies in ... stock before June 15, 2012 are encouraged to contact ... about their rights and remedies. "On ...
... Athens, Ga. University of Georgia scientists have discovered ... the immune system. Kimberly Klonowski, assistant professor of cellular ... Sciences, and her colleagues found that administering a cell-signaling ... reduces their peak viral load by nearly three times. ...
... Research Centre of Finland in collaboration with the University ... signature which predicts progression to Alzheimer,s disease months or ... occur. The goal of the new collaboration between VTT ... a large patient cohort as well as to discover ...
Cached Biology News:UGA study reveals flu-fighting role for well-known immune component 2VTT and GE Healthcare developing novel biomarkers to predict Alzheimer's disease 2